British Journal of Cancer, Published online: 29 July 2020; doi:10.1038/s41416-020-0989-1Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection
03:00
01:09
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Fri Jul 24, 2020 10:00
ABSTRACT A previous randomized phase 2 study of hepatocellular carcinoma revealed that the c‐Met inhibitor tivantinib as second‐line treatment significantly prolonged progression‐free survival in a subpopulation whose tumor samples highly expressed c‐Met (MET‐high). Accordingly, this phase 3 study was conducted to evaluate the efficacy of tivantinib as a second‐line treatment for Japanese patients with MET‐high hepatocellular carcinoma. This randomized, double‐blind, placebo‐controlled study was...
Mon Jul 27, 2020 13:40
Abstract Cervical cancer (CC) is usually initiated by infection with high‐risk types of HPV. The HPV E6 and E7 proteins target p53 and RB, respectively, but other cellular targets likely exist. We generated uterus‐specific MOB1A/B double KO (uMob1 DKO) mice, which immediately developed cervical squamous cell carcinoma in situ . Mutant cervical epithelial cells showed YAP1‐dependent hyperproliferation, altered self‐renewal, impaired contact inhibition, and chromosomal instability. p53 activation...
Mon Jul 27, 2020 13:40
Purpose: Atezolizumab has shown anti-tumor activity in patients with ovarian cancer. Dual blockade of programmed death-ligand 1 and vascular endothelial growth factor enhances anti-cancer immunity and augments anti-tumor activity in several cancers. The safety and efficacy of atezolizumab plus bevacizumab were evaluated in patients with ovarian cancer. Patients and methods: In this open-label, multicenter Phase Ib study, patients with platinum-resistant ovarian cancer received intravenous atezolizumab...
Tue Jul 28, 2020 16:10
Purpose: Small molecule inhibitors have had a major impact on cancer care. While treatments have demonstrated clinically promising results, they suffer from dose-limiting toxicities and the emergence of refractory disease. Considerable efforts made to address these issues have more recently focused on strategies implementing particle-based probes that improve drug delivery and accumulation at target sites, while reducing off-target effects. Experimental Design: Ultrasmall (<8 nm) core-shell silica...
Tue Jul 28, 2020 16:10
Purpose: Immune checkpoint blockade (ICB) has shown remarkable efficacy, but in only a minority of cancer patients, suggesting the need to develop additional treatment strategies. Aberrant glycosylation in tumors, resulting from the dysregulated expression of key enzymes in glycan biosynthesis, modulates the immune response. However, the role of glycan biosynthesis enzymes in anti-tumor immunity is poorly understood. We aimed to study the immunomodulatory effects of these enzymes. Experimental Design:...
Tue Jul 28, 2020 16:10
Purpose: To identify clinically relevant mechanisms of resistance to ER-directed therapies in ER+ breast cancer. Experimental design: We conducted a genome-scale functional screen spanning 10,135 genes to investigate genes whose overexpression confer resistance to selective estrogen receptor degraders. In parallel, we performed whole exome sequencing in paired pre-treatment and post-resistance biopsies from 60 patients with ER+ metastatic breast cancer who had developed resistance to ER-targeted...
Tue Jul 28, 2020 16:10
Publication date: Available online 27 July 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Callum G. Brownstein, Elisabeth Daguenet, Denis Guyotat, Guillaume Y. Millet
Tue Jul 28, 2020 16:02
Opinion statement Patients with borderline resectable pancreatic ductal adenocarcinoma (BR PDAC) should receive preoperative chemotherapy with or without radiation therapy, with the intent to eradicate occult metastatic cancer cells, to select patients with a “locally dominant cancer phenotype” for whom local therapies might be most effective, and to reduce the anatomic extent of tumors to facilitate surgical resection. The administration of preoperative therapy may also be...
Tue Jul 28, 2020 03:00
Opinion statement As a devastating complication of non-small cell lung cancer (NSCLC), the incidence of leptomeningeal metastasis (LM) is rising, largely due to overall longer survival of NSCLC, especially in patients with targetable molecular driver mutations. There is no clear consensus on the optimal management of LM. This review will cover recent advances in diagnosis, monitoring, and treatment of LM in NSCLC. In LM without oncogene drivers, systemic chemotherapy, intrathecal...
Tue Jul 28, 2020 03:00
Opinion statement Despite a decreasing incidence in the USA, gastric cancer is highly prevalent worldwide. Furthermore, gastric cancer remains highly lethal with median survival of less than 1 year for metastatic disease. The backbone of therapy against metastatic gastric cancer remains cytotoxic chemotherapy, but recent advances in the molecular understanding of gastric cancer have renewed hope within that targeted agents can be leveraged to improve survival and reduce toxicity....
Tue Jul 28, 2020 03:00
Opinion statement Oncology is the midst of a therapeutic renaissance. The realization of immunotherapy as an efficacious and expanding treatment option has empowered physicians and patients alike. However, despite these remarkable advances, we have only just broached the potential immunotherapy has to offer and have yet to successfully expand these novel modalities to the field of neuro-oncology. In recent years, exciting results in preclinical studies of immune adjuvants, oncolytic...
Tue Jul 28, 2020 03:00
Opinion statement Primary central nervous system lymphoma is a complex disease with no agreed-upon standard-of-care therapy. Induction therapy involves multiagent chemotherapy based on high-dose methotrexate, with several regimens available. We have a preference for a regimen using rituximab, methotrexate (3.5 g/m2), procarbazine, and vincristine (R-MPV) for initial induction therapy, given the favorable balance between toxicities and very high response rates (80–90%), which...
Tue Jul 28, 2020 03:00
Publication date: Available online 28 July 2020Source: European Journal of Surgical OncologyAuthor(s): Lingfu Zhang, Chunsheng Hou, Ming Chen, Limei Guo, Zhi Xu, Lixin Wang, Xiaofeng Ling, Gang Wang, Long Cui, Dianrong Xiu
Tue Jul 28, 2020 19:14
Publication date: Available online 28 July 2020Source: European Journal of Surgical OncologyAuthor(s): William R.C. Knight, Ricardo McEwen, Ben E. Byrne, Wais Habib, Rebecca Bott, Janine Zylstra, Ula Mahadeva, James A. Gossage, R.C. Fitzgerald, A. Noorani, P.A.W. Edwards, N. Grehan, B. Nutzinger, C. Hughes, E. Fidziukiewicz, S. MacRae, A. Northrop, G. Contino, X. Li, R. de la Rue
Tue Jul 28, 2020 19:14
Publication date: Available online 28 July 2020Source: European Journal of Surgical OncologyAuthor(s): Diwakar Pandey, Jitender Rohila, Vivek Sukumar, Avanish Saklani
Tue Jul 28, 2020 19:14
Publication date: Available online 27 July 2020Source: European Journal of Surgical OncologyAuthor(s): Itamoto Kota, Hikage Makoto, Kamiya Satoshi, Tanizawa Yutaka, Bando Etsuro, Terashima Masanori
Tue Jul 28, 2020 19:14
Related Articles Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncol. 2020 Jul 27;: Authors: Germetaki T, Nicholls C, Adams RA, Braun M, Rogan J, Moghadam S, Lenfert E, Lukas A, Edelstein DL, Jones FS, Saunders MP Abstract Aim: To determine the concordance between plasma and tissue RAS mutation status in metastatic colorectal cancer patients to gauge whether blood-based...
Tue Jul 28, 2020 14:20
Related Articles Implementation of breast cancer continuum of care in low- and middle-income countries during the COVID-19 pandemic. Future Oncol. 2020 Jul 27;: Authors: Elghazawy H, Bakkach J, Zaghloul MS, Abusanad A, Hussein MM, Alorabi M, Eldin NB, Helal T, Zaghloul TM, Venkatesulu BP, Elghazaly H, Al-Sukhun S Abstract Breast cancer is the most common malignancy among women worldwide. The current COVID-19 pandemic represents an unprecedented...
Tue Jul 28, 2020 14:20
Related Articles Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment. Future Oncol. 2020 Jul 26;: Authors: Abdul Rahman SF, Xiang Lian BS, Mohana-Kumaran N Abstract The B-cell lymphoma 2 (BCL-2) anti-apoptotic proteins have become attractive therapeutic targets especially with the development of BH3-mimetics which selectively target these proteins. However, it is important to note that expression levels of the...
Tue Jul 28, 2020 14:20
Related Articles Future directions in advanced penile cancer - mechanisms of carcinogenesis and a search for targeted therapy. Future Oncol. 2020 Jul 26;: Authors: Teh J, O'Connor E, O'Brien J, Lim WM, Taylor M, Heriot A, Ramsay R, Lawrentschuk N Abstract Penile squamous cell carcinoma (SCC) is a rare and aggressive urological malignancy. Advanced penile SCC requires multimodal management, including surgery and systemic therapy. Given its rarity,...
Tue Jul 28, 2020 14:20
Abstract Rearrangements of the MLLT10 gene occur in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), most commonly T‐lineage ALL (T‐ALL), in patients of all ages. MLLT10 rearranged (MLLT10 r) acute leukemia presents a complex diagnostic and therapeutic challenge due to frequent presentation of immature or mixed phenotype, and a lack of consensus regarding optimal therapy. Cases of MLLT10 r AML or T‐ALL bearing immature phenotype are at high risk of poor outcome, but the underlying...
Tue Jul 28, 2020 11:12
Abstract Whether adding carboplatin to standard neoadjuvant chemotherapy improves survival in BRCA1/2 ‐mutated triple‐negative breast cancer is unknown. In this retrospective study, we aimed to explore the efficacy of anthracycline‐taxane‐ or anthracycline‐taxane/carboplatin‐based neoadjuvant chemotherapy in BRCA1/2 ‐mutated triple‐negative breast cancer. 1,585 operable primary breast cancer patients were treated with either neoadjuvant anthracycline followed by taxane (A‐T) (n=886) or anthracycline...
Tue Jul 28, 2020 12:12
ABSTRACT Chromosome 14q32 rearrangements/translocations involving the immunoglobulin heavy chain (IGH ) are rarely detected in chronic lymphocytic leukemia (CLL). The prognostic significance of the IGH translocation is controversial and its mutational profile remains unknown. Here, we present for the first time a comprehensive next‐generation sequencing (NGS) analysis of 46 CLL patients with IGH rearrangement (IGHR ‐CLLs) and we demonstrate that IGHR ‐CLLs have a distinct mutational profile with...
Tue Jul 28, 2020 12:12
Journal of Adolescent and Young Adult Oncology, Ahead of Print.
Mon Jul 27, 2020 10:00
Journal of Adolescent and Young Adult Oncology, Ahead of Print.
Mon Jul 27, 2020 10:00
Journal of Adolescent and Young Adult Oncology, Ahead of Print.
Tue Jul 21, 2020 10:00
Journal of Adolescent and Young Adult Oncology, Ahead of Print.
Tue Jul 21, 2020 10:00
Journal of Adolescent and Young Adult Oncology, Ahead of Print.
Tue Jul 21, 2020 10:00
Abstract Italy was the first European country to be hit by COVID-19 pandemic. As a consequence, Italian oncologists had to guarantee essential treatments although minimizing exposure to the virus, and accidental infection, of patients and healthcare professionals. As Department of Medical Oncology of the University Hospital of Udine, in this short report, we describe the measures that we have taken, and gradually updated, since February 26, 2020. All accesses to our Oncology...
03:00
Abstract As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediate-risk prostate cancer treated with extreme hypofractionated radiotherapy (RT) and simultaneous boost to the intraprostatic lesion. The aim of the study is to identify clinically meaningful information through the analysis of validated questionnaires testing gastrointestinal (GI) and genitourinary (GU) RT-related toxicity and their impact on quality of life (QoL). At...
Tue Jul 28, 2020 03:00
Abstract Pituitary tumor-transforming gene 1 (PTTG1) has been identified as an oncogene and is overexpressed in many tumor types. However, the role of PTTG1 in glioblastoma (GBM) has not been well characterized, especially in relation to angiogenesis, migration, and invasion. In the present study, our results showed that the expression of PTTG1 was significantly higher in patients with GBM. Bioinformatic analysis showed that angiogenesis and the cell migration-related process...
Tue Jul 28, 2020 03:00
Abstract Cancer cells alter their metabolism by switching from glycolysis to oxidative phosphorylation (OXPHOS), regardless of oxygen availability. Metabolism may be a molecular target in acute myeloid leukemia (AML), where mutations in metabolic genes have been described. This study evaluated glycolysis and OXPHOS as therapeutic targets. The sensitivity to 2-deoxy-d-glucose (2-DG; glycolysis inhibitor) and oligomycin (OXPHOS inhibitor) was tested in six AML cell lines (HEL,...
Tue Jul 28, 2020 03:00
Abstract Purpose The purpose of this study was to describe the experiences of Korean family caregivers of patients with cancer by reviewing recent literature. Methods Five electronic databases were searched— MEDLINE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and PubMed for English literature, and Korean Information Service System (KISS), and Research Information Sharing Service (RISS) for Korean literature for articles published from January 2010 to March 2020...
Mon Jul 27, 2020 19:35
Abstract Objective This study examined the growth trajectory of fear of cancer recurrence (FCR) and its predictors, and the association of that trajectory with the beliefs and rates of medication adherence in patients with breast cancer. Methods 210 patients with breast cancer undergoing adjuvant endocrine therapy in a university hospital in Seoul, Korea, were followed up five times over 18 months following surgery, and data from the final 162 patients were analyzed. Results Latent...
Mon Jul 27, 2020 19:34
Publication date: Available online 28 July 2020Source: Reports of Practical Oncology & RadiotherapyAuthor(s): Afshin Rakhsha, Samira Azghandi, Farzad Taghizadeh-Hesary
Tue Jul 28, 2020 16:26
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου